Physician profile
Nadia Haque
NPI 1689922007
$642.83
in general payments reported to CMS, 2019-2025
14 companies · $99.42 in 2025
The $99.42 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $80.63 · 2021: $73.75 · 2022: $90.36 · 2023: $48.94 · 2024: $131 · 2025: $99.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $122.78 | 2019-2022 | |
| Corium, LLC | $111.77 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $99.62 | 2020-2021 | |
| Tris Pharma INC | $51.23 | 2020-2025 | Dyanavel Xr |
| Cumberland Pharmaceuticals, INC. | $46.27 | 2023-2024 | Kristalose |
| Sanofi-Aventis U.S. LLC | $41.12 | 2024-2025 | |
| Glaxosmithkline, LLC. | $32.31 | 2019-2022 | |
| Genentech USA, INC. | $26.80 | 2020 | |
| Lnhc, INC | $22.67 | 2025 | Zelsuvmi |
| Abbvie INC. | $22.54 | 2022 | |
| Pfizer INC. | $17.97 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.22 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.11 | 2021 | |
| Merck Sharp & Dohme LLC | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.